Jama 305(5):487–494. 43. Verma N, Swain SM: Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol 29(6):603–606. 44. Hayes DF: Bevacizumab treatment for solid tumors: boon or bust? Jama

305(5):506–508. Competing interests The GW786034 clinical trial Authors declare that they have no competing interests. selleck chemical Authors’ contributions FCu, EB, VV, PC, MM and SG conceived the analysis, and supervised the calculations; FCu, EB, IS, and DG performed the calculations in a blinded fashion; VV, FB, AF, PC, MM, CN, MR, PP, and GF participated in the trials recruitment and selection process; FCu, EB, VV, FP, AF and MM drafted and revised the manuscript; EB, PC, MM, MA, DG and FC did coordinate the overall study process

and did provide the funding. All authors read and approved the final manuscript.”
“Correction After publication of this work [1], we noted that we inadvertently made an error order of author affiliations. The corrected order of author affiliations was listed as above. References 1. Guo-Qing P, Yuan Y, Cai-Gao Z, Hongling Y, Gonghua H, Yan T: A study of association between expression of hOGG1, VDAC1, HK-2 and cervical carcinoma. J Exp Clin Cancer Res 2010,29(1):129.PubMedCrossRef Competing interests Dr Guo-qing P and Yan T made main contribution for this works, and have consulted the other authors in competing interests. They declare CDK inhibitor no conflicts of interest. Authors’ contributions PGQ and TY designed the study and collected the cervical biopsy samples, YY wrote the main manuscript, HGH performed data analysis, YHL accomplished pathological diagnosis, ZCG looked over the manuscript. All authors read and approved the final manuscript.”
“Background Irradiation techniques with Intensity Modulated Radiotherapy (IMRT) allow doses to be delivered to the target

with a high conformation of prescribed isodose, sparing Organs at Risk (OARs), compared to conventional 3D-CRT techniques. Another advantage of the IMRT technique is the possibility to achieve the so-called Simultaneous Integrated Boost (SIB), which provides different levels of therapeutic doses to different target volumes during the same treatment session, once the Flavopiridol (Alvocidib) fraction number has been set [1–5]. Historically, to obtain the desired tumor control, the doses were determined using a conventional fractionation that ranged between 50 to 70 Gy at 2 Gy per fraction. Whereas, in order to obtain Tumor Control Probability (TCP), equivalent to that of a conventional fractionation, the total dose simultaneously delivered to the targets have to be determined according to the Linear Quadratic Model (LQM) to be used with the SIB technique [6]. Thus, the dose per fraction to PTVs and/or boost may differ by 2 Gy per fraction.